FENNEC PHARMACEUTICALS INC. (FENC) Current Ratio
- Current ratio · latest quarter: Value 5.85×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 5.85× | Current assets / current liabilities. $72.50M ÷ $12.39M ≈ 5.85× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 72.50M USD | Assets, Current |
| Current obligations | 12.39M USD | Liabilities, Current |
| Cash and equivalents | 41.25M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 5.52M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $72.50M | $12.39M | $41.25M | (m) | (m) | (m) | $5.52M | (m) | 5.85× |
| 2026-03-31 | $66.88M | $9.59M | $40.18M | (m) | (m) | (m) | $6.28M | (m) | 6.98× |
| 2025-12-31 | $67.04M | $10.52M | $36.79M | (m) | (m) | (m) | $4.63M | (m) | 6.37× |
| 2025-09-30 | $46.06M | $9.81M | $21.95M | (m) | (m) | (m) | $5.87M | (m) | 4.69× |
| 2025-06-30 | $40.79M | $8.41M | $18.70M | (m) | (m) | (m) | $5.94M | (m) | 4.85× |
| 2025-03-31 | $42.98M | $8.37M | $22.68M | (m) | (m) | (m) | $5.28M | (m) | 5.13× |
| 2024-12-31 | $44.12M | $6.92M | $26.63M | (m) | (m) | (m) | $3.24M | (m) | 6.38× |
| 2024-09-30 | $57.97M | $7.43M | $40.32M | (m) | (m) | (m) | $3.87M | (m) | 7.80× |
| 2024-06-30 | $62.17M | $7.75M | $43.05M | (m) | (m) | (m) | $4.45M | (m) | 8.02× |
| 2024-03-31 | $68.17M | $9.84M | $51.18M | (m) | (m) | (m) | $5.20M | (m) | 6.93× |
| 2023-12-31 | $26.86M | $7.55M | $13.27M | (m) | (m) | (m) | $3.78M | (m) | 3.56× |
| 2023-06-30 | $19.33M | $3.78M | $14.96M | (m) | (m) | (m) | $3.00M | (m) | 5.12× |
| 2023-03-31 | $21.66M | $4.02M | $18.39M | (m) | (m) | (m) | $2.95M | (m) | 5.39× |
| 2022-12-31 | $26.73M | $4.61M | $23.77M | (m) | (m) | (m) | $2.39M | (m) | 5.80× |
| 2022-09-30 | $30.15M | $2.93M | $29.75M | (m) | (m) | (m) | $2.53M | (m) | 10.30× |
| 2022-06-30 | $15.55M | $3.04M | $14.91M | (m) | (m) | (m) | $1.74M | $1.00M | 5.12× |
| 2022-03-31 | $19.13M | $2.14M | $18.26M | (m) | (m) | (m) | $1.22M | $500.00K | 8.96× |
| 2021-12-31 | $22.39M | $1.65M | $21.10M | (m) | (m) | (m) | $777.00K | (m) | 13.54× |
| 2021-06-30 | $28.07M | $848.00K | $27.29M | (m) | (m) | (m) | $677.00K | (m) | 33.11× |
| 2021-03-31 | $27.82M | $2.89M | $26.75M | (m) | (m) | (m) | $2.51M | (m) | 9.62× |
| 2020-12-31 | $31.42M | $2.35M | $30.34M | (m) | (m) | (m) | $1.57M | (m) | 13.39× |
| 2020-09-30 | $34.07M | $2.88M | $33.17M | (m) | (m) | (m) | $2.68M | (m) | 11.81× |
| 2020-06-30 | $38.90M | $3.19M | $38.73M | (m) | (m) | (m) | $2.75M | (m) | 12.19× |
| 2020-03-31 | $10.12M | $1.91M | $9.90M | (m) | (m) | (m) | $1.68M | (m) | 5.31× |
| 2019-12-31 | $13.88M | $2.27M | $13.65M | (m) | (m) | (m) | $1.61M | (m) | 6.11× |
| 2019-09-30 | $15.63M | $905.00K | $15.24M | (m) | (m) | (m) | $788.00K | (m) | 17.27× |
| 2019-06-30 | $17.53M | $1.35M | $17.48M | (m) | (m) | (m) | $1.23M | (m) | 12.96× |
| 2019-03-31 | $20.34M | $1.45M | $20.23M | (m) | (m) | (m) | $1.30M | (m) | 14.02× |
| 2018-12-31 | $22.95M | $1.64M | $22.78M | (m) | (m) | (m) | $1.03M | (m) | 14.02× |
| 2018-09-30 | $24.93M | $2.08M | $24.52M | (m) | (m) | (m) | $1.87M | (m) | 12.01× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |